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 Summary: 
In recent years intense research has been carried out in Chronic Obstructive Lung Disease (COPD).The methods for 
physiological examination and classification of COPD patients have not developed during this period. This PhD thesis 
investigates the association between the tools used to investigate and characterize COPD as well as the influence of the 
presence of comorbidities on these associations. Furthermore, it investigates the need for development of new tools to 
investigate lung function in COPD patients in order to obtain a more detailed knowledge of the character of the disease 
in the individual.  
The Automatic Lung Parameter Estimator (ALPE) has, over the last decades, been developed as a method for 
measuring pulmonary gas exchange. The method is primarily used in intensive care. In this thesis, the assumptions 
behind the ALPE method are investigated to elucidate the possibility of future use in COPD patients. ALPE uses 
oxygen as a tracer gas and the method is based on several assumptions concerning oxygen. ALPE measures oxygen 
steady state at different levels of inspired oxygen and it is assumed that, in COPD patients as in healthy individuals, 
oxygen steady state is reached within a few minutes of changes in inspired oxygen. When oxygen is changes stepwise, 
the saturation of the blood is reduced. It is assumed that the changes in saturation do not cause changes in pulmonary 
circulation to an extend that has any influence on either the patient’s well-being or on the result of the ALPE 
examination. These assumptions are evaluated in this thesis.  
The thesis is based on four studies. The first study investigates the influence of presence of comorbidities on the 
outcome of currently available measures of disease severity and lung function as well as radiological examinations in 
COPD patients. The second study investigates the relationship between diffusion capacity of the lung and changes in 
oxygenation of the blood. In the third study, time to oxygen steady state following changes in inspired oxygen in 
patients with very severe COPD and chronic respiratory failure was examined. In the fourth study, changes in 
pulmonary arterial pressure and pulmonary resistance in response to the changes in inspired oxygen were examined in a 
group of postoperative patients who had undergone cardiac surgery.  
The first study indicated that evaluation methods for COPD are influenced by the presence of comorbidities. The 
second study showed that diffusing capacity was not associated with changes in oxygenation but rather with systemic 
parameters. These studies indicate that more specific tools for evaluation of COPD patients are needed.  
The third study showed that in patients with very severe COPD oxygen steady state occurs 16 minutes after changes in 
inspired oxygen.  
The fourth study showed that the changes in the oxygen saturation as induced by changes in inspired oxygen during the 
ALPE measurement only results in limited changes in the pulmonary arterial pressure and – resistance and that these 
changes are immediate reversible when inspired oxygen is returned to baseline.  
In conclusion, this thesis shows the present evaluation methods in COPD are very susceptible to the presence of 
comorbidities. Therefore new tools for physiological examination of COPD patients could be beneficial and that the use 
of ALPE, with modifications, is a possible future modality in COPD diagnostics and assessment. 
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 Abbreviations 
 
ALPE: Automatic Lung Parameter Estimator 
BMI: Body Mass Index 
CAT: COPD Assessment Score 
CCQ:  Clinical COPD Questionnaire 
COPD: Chronic Obstructive Pulmonary Disease 
ΔCO2:  end tidal PCO2 - arterial PCO2 
CT: Computed Tomography 
FEV1: Forced Expiratory Volume in the first second 
FiO2: Inspired oxygen fraction  
FVC: Forced Vital Capacity 
GOLD:  Global initiative for chronic Obstructive Lung Disease 
HPV: Hypoxic Pulmonary Vasoconstriction 
HR-CT: High Resolution Computed Tomography 
IC: Inspiratory Capacity 
LTOT: Long Term Oxygen Therapy 
MIGET:  Multiple Inert Gas Elimination Technique 
MRC: Medical Research Council Score 
mMRC: modified Medical Research Council Score 
MPAP: Mean Pulmonary Arterial Pressure 
MRI: Magnetic Resonance Imaging 
PCO2: Partial pressure of Carbon Dioxide in the blood 
PO2:  Partial pressure of Oxygen in the blood 
PVR: Pulmonary Vascular Resistance 
SpO2: Peripheral oxygen saturation 
T90:  Time to reach 90% of the final value of oxygen steady state 
TLC: Total Lung Capacity 
V̇/Q̇: Ventilation/perfusion 
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Chapter 1: Background 
1.1 Introduction 
Chronic obstructive pulmonary disease (COPD) is characterised by a progressive and irreversible 
decline in lung function. Different types of physiological assessment are used for diagnosing 
COPD, to evaluate disease severity, as well as to understand the symptoms of patients with COPD. 
However, it has been acknowledged that physiological measurements used to assess COPD patients 
have limitations when demonstrating functional pathophysiology [1]. A tool not previously 
investigated in COPD, the Automatic Lung Parameter Estimator (ALPE), may be of use for this in 
the future. 
    This thesis investigates the adequacy of, and the relationship between, the different assessment 
tools we have to diagnose, understand and evaluate COPD patients. It includes consideration of 
comorbidities and investigates the impact they have in the evaluation of COPD. In continuum of 
this, it questions the need to augment possibilities of investigating pathophysiology of COPD in 
clinical care. This leads to the question of ALPE as a bedside tool for investigating lung function in 
COPD. However, before considering this, the assumptions behind its use in clinical care require 
further evaluation, both in general and for COPD patients in particular.  
    This first chapter provides information on the impact, complexity and nature of COPD and 
presents the pathophysiological measurements obtained in COPD patients from the tools at our 
disposal today. Furthermore, it introduces the clinical assessment tools used to stratify disease 
severity. Lastly, it discusses the potential pitfalls of combining the information obtained from the 
different types of assessment used in the evaluation of COPD. 
  
1.2 COPD – mortality and social impact 
COPD has become the most important respiratory disease on a global scale. The Global initiative 
for chronic Obstructive Lung Disease (GOLD) has estimated that 210 million people suffer from 
COPD worldwide [2], and in Denmark the prevalence of COPD is estimated to 9% in Danes aged 
above 45 years [3]. Globally, COPD now causes 5% of all deaths and is predicted to increase to 30 
% over the next 10 years in low-, middle- and high-income countries [4–6].  
    The socio-economic expenditure in connection with COPD, both health care-related costs and 
costs for social benefits, has increased considerably in recent years and is comparable to that of 
stroke in the western world population [7–9]. Furthermore, the expenditure associated with COPD 
is larger than the expenditure associated with other chronic diseases, such as heart disease and 
10 
 
cancer [10]. The expenses are primarily associated with the large number of patients who have 
numerous comorbidities[11]. 
 
1.3 COPD and comorbidity 
COPD patients are predisposed to comorbidities, with this being an important cause of the increased 
mortality and morbidity seen in this disease [12,13]. Indeed, the GOLD recommends assessment of 
comorbidities in all COPD patients [2]. The incidence of comorbidities has been shown to rise with 
increased dyspnea and disease severity [14]. The high prevalence of comorbidity is likely to be 
multifactorial, and is associated with age and the excess risk of mortality and morbidity due to 
tobacco exposure [13,15]. However, even when controlling for common risk factors such as 
smoking, conditions as cardiac disease and type 2 diabetes, are even more prevalent than should be 
expected in patients suffering from COPD [16,17]. Thus, it has been suggested that COPD may, to 
some extent, be part of a metabolic syndrome [18]. The frequent co-existence of COPD, diabetes 
and heart disease has lead to speculations of a common inflammatory genesis [19,20], and has 
suggested an inflammatory phenotype of COPD [21]. In patients with concomitant COPD and 
cardiac disease, both diseases are often under-diagnosed [22], and even when recognized, they 
remain undertreated [23]. A recent study by Garcia-Olmos et al has found that 90 % of COPD 
patients in general practice had comorbidities, in average 4 per patient, and a study by Divo et al 
found 6 comorbidities per patient in tertiary care [16,24]. The prevalence of the 10 most common 
comorbidities in both studies are presented in Figure 1, which shows that malignancies, ischemic 
heart disease and anxiety are more prevalent in patients handled in tertiary care. These 
comorbidities have all been associated with a higher risk of death [16,25] and morbidity [26–30].  
0
10
20
30
40
50
60
AHT Lip Dia BPH AND CAR Mal PAD Thy IHD CRF CHF DJD
Garcia-Olmos
Divo
Figure 1: The 10 most common comorbidities in the studies from Garcia-Olmos [24] and Divo [16]. ART = 
Arterial hypertension, Lip = Hyperlipidemia, Dia = Diabetes, BPH = benign prostatic hypertrophy, AND = 
Anxiety/Depression, CAR = Cardiac arrhythmia, Mal = Malignant disease, PAD = Peripheral arterial disease, 
Thy = Thyroid disease, IHD = ischemic heart disease, CRF = Chronic renal failure, CHF = Congestive heart 
failure, DJD = Degenerative joint disease. In addition, Divo registered obesity in 34 % of patients; this 
parameter was not included in the figure as it was not included in study by Garcia-Olmos.  
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Thus, one could hypothesize that, as patients with more severe COPD are allocated to tertiary 
centres, the comorbidities in themselves may influence our assessment of COPD severity. 
 
1.4 COPD: The pathological process 
 Development of COPD is caused by persistent pulmonary irritation. This affects not only the  
 
 
Figure 2: Simplified model of COPD pathology illustrating important pathways resulting in changes in small 
airways, inflammation causing mucus secretion, development of emphysema and vascular hypertrophy. 
Transforming growth factor- β (TGF-β), and interleukin (IL) 1, 6 and 8 derives from the epithelium and induces 
fibrosis in the small airways. Tumour necrosis factor-α (TNF-α) production increase and vascular endothelial 
growth factor (VEGF) decrease in the epithelium and cause vascular changes. Macrophages stimulate 
neutrophils and both cause activation of metalloproteinases, which induces development of emphysema. 
Macrophages also stimulate lymphocytes and monocytes, which, together with neutrophils, cause inflammation. 
Macrophages also release reactive oxygen species (ROS) which both stimulate inflammation and predispose to 
infections, which may cause disease progression.  
12 
 
 
airways, but also the parenchyma and pulmonary vasculature. This leads to complex pathological 
processes as demonstrated in a simplified model of COPD pathology in Figure 2. As COPD 
pathology is not the topic of this thesis this will not be described in further detail.  
 
1.5 Assessment of lung function in COPD  
Pathological changes lead to changes in pulmonary physiology. In daily clinical practice, lung 
function measurements allow quantification of the physiological impact of the pathological changes 
seen in COPD. However, as the pathophysiology of COPD is complex, complementary measures of 
lung function may be needed to assess different aspects of the disease. The five available 
assessment tools used in COPD patients will be described here, including their respective strengths 
and limitations. 
1.5.1 Spirometry  
Lung function is primarily measured in 
COPD using spirometry. Spirometry 
measurements of airway obstruction are 
used in determining the diagnosis of 
COPD [2]. Values of forced expiratory 
volume in the first second (FEV1), 
forced vital capacity (FVC) and the ratio 
between these, FEV1/FVC, are obtained from expiratory curves, describing volume/second (Figure 
3). A post bronco-dilator value of FEV1/ FVC below 0.7 is diagnostic of COPD, and impairment of 
FEV1% is commonly used as a description of disease severity [31].  
    FEV1 is currently used to describe the severity of lung function impairment in COPD, yet to 
evaluate the results, one has to be critical and ask: What does FEV1 reflect in COPD patients?  
Older studies have shown that a decline in FEV1 is predictive of mortality in COPD [32]. 
Furthermore, it has been shown that the number of exacerbations, (further explained in chapter 
1.7.2), are associated with decline in FEV1[33]. Moreover, fibrosis, inflammation and luminal 
secretions in the small airways of COPD patients has also been shown to correlate with FEV1 
reduction [34]. As such FEV1 has been the primary assessment tool to evaluate treatment efficacy 
in COPD [35]. 
Figure 3: A normal spirometry, volume (L)/time (sec).  Red 
arrow: FEV1, green arrow: FVC 
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    Spirometry may be thought of as a simple procedure but has proved to be difficult to perform, 
with as many as 40 % of spirometries performed in clinical respiratory laboratories deemed to be 
not acceptable [36]. A Danish study found that 15 % of all spirometries performed in general 
practice were inconclusive as the duration of the procedures were too short for FVC to be reached 
[37]. Moreover, FEV1 only partially reflect patients’ self-evaluated dyspnea and general health [38–
40]; symptom severity such as cough and sputum production do not to correlate to decline in FEV1 
[41,42]; FEV1 does not reflect systemic inflammation, as no association between neutrophils and 
FEV1 impairment has been shown [43].         
    As a result the GOLD group has stated that FEV1, as a solitary measure, does not clearly depict 
disease severity in the individual [2]. Spirometry, therefore, cannot provide us with a complete 
description of COPD. Additional measurements of the patient's pulmonary pathophysiology may be 
obtained from other methods such as body plethysmography. 
 
1.5.2 Body plethysmography  
In COPD body plethysmography provides additional measures to describe functional and structural 
aspects of the disease. 
    The measurements that can be obtained from plethysmography are illustrated in Figure 4. Of 
these inspiratory capacity (IC) and total lung capacity 
(TLC) are discussed in further detail below, as these have 
been shown to be important measures in patients with 
COPD [44]. Both relate to hyperinflation, which is 
defined as an increase in operating lung volumes (i.e. 
shifting lung volumes during work) above resting values. 
Hyperinflation occurs as a consequence of expiratory 
flow limitation, caused by increased airway resistance 
instigated by the diminished lumen of the airway [44]. 
Dynamic hyperinflation is characterized by dynamic 
changes in IC alone [45] whereas IC/TLC is a measure of 
static – or passive - hyperinflation [46]. In COPD, 
hyperinflation is an independent risk factor of morbidity 
and mortality [17,47–49]. 
Both IC and IC/TLC alone are strongly associated with dyspnea [46,50] which is consistent with 
the decrease in dyspnea and IC seen in response to treatment with long-acting muscarinic 
Figure 4: Absolute gas volumes as 
measured by body plethysmography: 
TLC, total lung capacity; VT, tidal 
volume; IC, inspiratory capacity; FRC, 
functional residual capacity; ERV, 
expiratory reserve volume; VC, vital 
capacity; RV, residual volume. 
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antagonists [51,52]. TLC has been shown to increase significantly with disease progression [53]. 
There has been conflicting results on whether TLC as a isolated measure is predictive of mortality 
in COPD, with no association between TLC and mortality in COPD in general [54], however an 
association between TLC and mortality has been suggested in patients with emphysema [47]. 
    The use of body plethysmography has its shortcomings, as it is limited to tertiary care-, and, in 
some instances, secondary care institutions. This is largely due to the fact that it can only be 
operated by specially trained healthcare personnel, who need to perform the examinations regularly 
to secure that standards are kept. This is also the case for diffusing capacity of the lung for carbon 
monoxide (DLCO), described in the next section. 
1.5.3 Diffusing capacity of the lung for carbon monoxide  
DLCO measures the transfer of gas from alveolar air to the erythrocytes passing through the 
pulmonary capillaries. It is a composite measure, which may be influenced by a number of 
abnormalities of ventilation, perfusion, diffusion, and properties of the blood as demonstrated in 
Figure 5.  
    The term “diffusing capacity” is actually misleading; neither is diffusion really measured nor is 
the obtained value a capacity, but a conductance. The term transfer factor may be used instead; 
however, diffusion capacity remains the most common term in clinical practice, and is therefore 
used throughout the thesis. 
    In COPD, DLCO has been shown to be 
associated with the degree of emphysema 
as evaluated by computered tomography 
(CT) scans [55–57]. Furthermore it has 
been shown to be associated with dyspnea 
in COPD [58] and to be predictive of 
functional decline in COPD [59]. 
Interestingly, DLCO has also been shown 
to be associated with body mass index 
(BMI), both in the general population 
[60,61] and in COPD patients [62,63]. 
Additionally, other systemic diseases, 
frequently seen as comorbidities in COPD, may also influence DLCO. In heart failure impaired 
DLCO has been seen in several studies, [64–66], even with preserved ejection fraction [67]. 
Figure 5: Reduction in DLCO with A: (no pathology) as 
reference picture: 
B: anemia C: high carboxy-hemoglobin levels D: 
thickening of the alveolar membrane E: pulmonary 
vascular disease causing impaired blood flow F: 
hemoglobinophathy. With permission from [201]. 
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Furthermore in COPD patients with comparable FEV1, DLCO been found to be significantly lower 
in patients with concomitant type 2 diabetes [68,69]. Changes in DLCO in diabetes seem to be 
independent of heart disease [70]. Taken together, changes in DLCO may be caused by a number of 
different diseases, including pulmonary disease. The physiological measures used in daily clinical 
practice such as DLCO are simplified approximations of the underlying complex physiological 
measures. These are not therefore not able to describe abnormalities of pulmonary gas exchange in 
detail [71]. The development of the Multiple Inert Gas Elimination Technique (MIGET) by P.D. 
Wagner and colleagues in the 1970’s provided a novel method which overcame these limitations 
[72]. 
 
1.5.4 The Multiple Inert Gas Elimination Technique  
MIGET is based on the principle of the relationship between the ventilation/perfusion ratio (V̇/Q̇ 
ratio) and the alveolar and capillary partial pressures of any gas. The method includes intravenous 
infusion of 6 dissolved inert gasses and calculates pulmonary exchange, using a mathematical 
model comprised of 50 compartments with different V̇/Q̇ ratios. In this way a quantification of the 
distribution of V̇/Q̇ mismatch in the individual patient can be obtained [73].  
    Using MIGET, it has been shown that V̇/Q̇ mismatch is present even in very mild COPD [74,75], 
and measurement of V̇/Q̇ abnormalities could therefore be a help in early diagnosis of the disease. 
In the 1970’s Wagner et al. showed that both areas of high and low V̇/Q̇ ratio may be seen in the 
individual COPD patient and that it is necessary to describe both, to fully understand gas-exchange 
impairment in COPD [74].Wagner and colleagues divided patients into clinical subgroups based on 
their V̇/Q̇ ratio: patients with predominantly high V̇/Q̇ ratios who typically suffered from alveolar 
wall destruction, and patients with predominantly low V̇/Q̇ areas who typically presented with 
symptoms of severe cough and sputum production [74].  
    The MIGET provides a detailed description of impairment of pulmonary gas exchange. However, 
the method is time consuming, costly and requires personnel with high expertise. These factors limit 
the use of the method in clinical care and in research including large study populations.  
    However, the MIGET not only quantifies the result of the pathophysiological changes, it also 
unmasks the underlying pulmonary pathology, which physiologically may help to identify different 
phenotypes. Today no single clinically available physiological method provides us with this 
phenotypic classification knowledge. A simple, inexpensive, easy-to-operate alternative 
measurement could be wished for.  
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1.6 Computed tomography in COPD 
CT-scans are able to illustrate details of both lung parenchyma and the bronchial system, in contrast 
to conventional two-dimensional chest x-rays. CT-scans are increasingly used in imaging COPD, 
mainly due to the decreased radiation doses needed for the procedure [76,77]. The use of CT-scans 
has underlined the complexity and diversity of the pathophysiology of the COPD lung. In COPD, 
two main features are described in CT scans; 1) emphysema and 2) airways disease. High 
Resolution CT (HR-CT) has particular advantages in diagnosing and describing the severity of 
emphysema very accurately [78]. 
These features may be evaluated either by qualitative and quantitative methods or in combination of 
the two [79].  
    Emphysema: When evaluated from CT-scans, a recognized 
quantitative method is a threshold technique, the “Density 
Mask Method”, which measures areas of a density <-910 to -
950 Hounsfield. This threshold still needs to be finally 
standardized to the ranges of normal lungs [80]. The Density 
Mask Method is often used in combination with qualitative 
interpretation of CT-scans, where various algorithms to 
support the observer’s evaluation exist. In a qualitative 
evaluation radiologists classically distinguish between three 
types of emphysema: Centrilobular , panlobular and 
paraseptal emphysema [81]. Figure 6 shows an example of 
centrilobular emphysema, which typically emanates from the 
secondary pulmonary lobule close to the proximal respiratory 
bronchiole, and is often seen in the upper lobes [77,78]. 
Figure 7 shows an example of pan lobular emphysema, which 
may be present in all parts of the lung. It occurs as a result of 
loss of acini characterized by a diffuse decrease in lung 
attenuation [83]. Figure 8 shows an example of paraseptal 
emphysema, which is less common and most often occurs in 
rows along the pleura in the upper lobes.  
 
Figure 6: CT scan of patient with 
centrilobular emphysema (red 
arrow). Scan from study 1. 
(C11population 
Figure 7: Pan lobular emphysema 
with the red arrow pointing to the 
affected lobe. Scan from study 1.  
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Figure 8: Paraseptal emphysema, with progressive disease severity moving left to right in the figure. Red 
arrows illustrating the areas of the lung affected with paraseptal emphysema. The blue arrows illustrate 
areas of concomitant centrilobular emphysema. Scans from study 1.  
 
Paraseptal emphysema does not usually impair lung function unless the disease has progress to a 
state with large bullae [83].  
COPD-patients often present with a combination of the different subtypes, as seen in Figure 8 [83]. 
    Airway disease is not easily interpreted in CT scans. Although bronchial biopsies from patients 
presenting with cough and sputum reveal bronchial wall thickening and airway inflammation [84], 
bronchial wall thickening is only visible in 19 % of CT-scans from symptomatic patients with a 
inter-observer agreement of only 18-28% [85], and a small in-vivo/ex-vivo study showed that only 
39% of airways disease was visible in HR-CT [86].  
    Considered an accurate diagnostic tool the use of CT and HR-CT in COPD has increased 
considerably in this century, the method described as an [87]. However, the association between CT 
findings and other measures of COPD has ambiguous. As such, studies investigation the association 
between CT- and HR-CT findings in COPD versus spirometric measures have shown conflicting 
results, with no to moderate association found [88–92]. A stronger association is found between 
CT- and HR-CT findings in COPD and DLCO [58,93]. Furthermore significant associations, 
although moderate in strength the association have been shown between CT- and clinical 
manifestations of COPD, such as six minute walking test and dyspnea [58,94,95]. The explanation 
of these not very convincing results may be related to the challenges of evaluating CT-scans, as 
described above [76,96]. Moreover, the clinical manifestations associated with COPD are 
influenced by other parameters than pulmonary changes [97]. However, CT scans may be superior 
to the traditionally lung function assessment tools in detecting and describing COPD [98], 
especially in patients presenting emphysematic changes, as these are visible before physiological 
derangement in lung function [99,100].  
    Despite the decrease of the radiation dose administered to the patients, the use of CT still poses a 
risk to the patient. The use of the method is also limited by examination costs and, in some parts of 
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the world, limited availability [101]. In addition, in the most severely ill COPD patients, a CT scan 
may be an ordeal, with breath holding while lying flat being very uncomfortable for these patients.  
1.7 Patient reported outcomes and assessment of severity in COPD 
Individual measurements are rarely sufficient to give the full clinical picture of the COPD patient. 
As such, in clinical practice, measurements are often used in combination with patient reported 
outcomes to obtain a more complete assessment of the patient. Valuable information is gained from 
different patient reported outcomes, as for example the modified Medical Research Council 
(mMRC) score and the number of exacerbations in the preceding year. A combined risk assessment 
score has been developed by the GOLD initiative for stratification of COPD patients. To improve 
readability this has been shortened to the GOLD stratification score throughout the thesis. The 
GOLD stratification score is a composite measure of lung function and patient reported outcomes, 
i.e. mMRC and exacerbations in the preceding year. Both the patient reported outcomes and the 
GOLD stratification score are presented in this section, which also discusses the strengths and 
limitations of the score. 
1.7.1 Dyspnea and the Medical Research Council Score 
Patients with COPD experience slowly progressing dyspnea and disability. Traditionally, the impact 
of dyspnea has been described by the Medical Research Council (MRC) score [102]. The MRC 
score is based on studies of Welsh coal miners in the Medical Research Council’s pneumoconiosis 
unit in the 1940’s. A modified version, the mMRC score, was presented in the late 1980’s in order 
to exclude quantification of potentially healthy individuals during exercise [103]. The score has 
been shown to describe patients’ disability [104,105], with up to 98% inter-observer agreement 
when repeating questioning [103].  
    In itself, the mMRC does not quantify breathlessness, but an unexpected level of breathlessness 
at a given level of activity, which could be described as “inappropriate breathlessness”. The mMRC 
score is one of three suggested symptom scores to be used in the GOLD stratification score; 
alternative measures are the COPD Assessment Test (CAT) [106], and the clinical COPD 
Questionnaire ( CCQ) [107]. These scores are not described in detail as only the mMRC score was 
used as symptom score in this thesis.  
1.7.2 Exacerbations of COPD 
The number of exacerbations varies greatly in COPD-patients and it has been shown that the best 
predictor for having future exacerbations are exacerbations in the past [108]. One-fourth of COPD 
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patients are frequent exacerbators, determined as ≥ 2 exacerbations per year [109] and recurrent 
exacerbations become more frequent with decrease in lung function [108]. Exacerbations of COPD 
are associated with mortality and morbidity [110–112]. Furthermore, hospitalization due to 
exacerbation is predictive of future hospitalizations and death [113–116]. With an impact on 
morbidity and mortality it is evident that exacerbations have massive impact on COPD patients and 
therefore, not surprisingly, also on patients’ quality of life [117]. The number of exacerbations in 
the preceding year has been included as a risk factor in the GOLD stratification score, described 
below.  
1.7.3 The Global Initiative for COPD  
The GOLD initiative was launched in 1997 in collaboration with the National Heart, Lung, and 
Blood Institute, National Institutes of Health, USA, and the World Health Organization. The aim of 
GOLD is to supply the clinical community with guidelines for COPD care, created by committees 
of leading experts from around the world. The initial version of the GOLD guideline was presented 
in 2001[2] and it undergoes revision every 5 years, with the latest major review having taken place 
in 2011 [118]. The guideline includes recommendations for disease stratification in terms of 
assessment of disease severity and for treatment of COPD. The goal of GOLD COPD assessment is 
to 
 
 “Determine the severity of the disease, its impact on patient’s health status, and the risk 
of future events (exacerbations, hospital admissions, death) in order to guide therapy.” 
    Previously, assessment of COPD severity has been determined alone by spirometric values [119]. 
Yet, as stated previously by Alvar Agusti, FEV1 alone cannot describe the complexity of the 
disease [120], nor does airflow limitation capture the heterogeneity of COPD [121]. These and other 
observations lead to changes in the latest revision of the GOLD recommendations [2], (now no 
longer called guidelines), where diagnosis by spirometry is augmented with patient reported 
outcomes, as evaluation of symptoms and future risk of exacerbations, in the final assessment of the 
patient, using the combined risk assessment score. 
1.7.4 The GOLD combined risk assessment score  
The GOLD stratification score stratifies patients in four groups, A-D, with group A representing the 
least severe COPD and D the most severe. 
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FEV1%<50 C D 
2 or more exacerbations per 
year/1 hospitalised exacerbation 
FEV1%≥50 A B 0-1 exacerbation per year 
                                                    mMRC 0-1; CAT<10  or CCQ≤ 1             mMRC 2-4 OR CAT>10 CCQ>1         
 
Patients are scored according to lung function, evaluated by spirometry; symptom score, in this 
thesis the mMRC is used, as mentioned above; and the number of exacerbations in the preceding 
year, using the model in Figure 9. 
    The present GOLD score has proved better at describing the longitudinal behaviour of COPD 
than the previous GOLD guidelines; as such the risk of exacerbation and hospitalization increases 
from group A to D, as does mortality [122]. Perhaps surprisingly, the mortality of patients in group 
B has been shown to exceed that of patients in group C [122,123]. A possible explanation could be 
that COPD patients with comorbidities have been shown to be found primarily in groups B and D 
[123,124]. As such the presence of comorbidities has previously been shown to increase mortality 
[125]. Furthermore health related quality of life have been shown to decrease from A to D; however 
similar to the above mentioned group C has been shown to have a better quality of life than group B 
[126]. Interestingly, the presence of comorbidities has also been shown to negatively influence the 
quality of life in COPD [28].     
    The GOLD score illustrated in figure 9 has led to clear improvements in disease stratification. 
Despite this, there is still several limitations of the GOLD score, for example: 
 Patient evaluation of numbers of exacerbations: The number of exacerbations either may be 
under- or over-estimated. Under-estimation can occur due to patients’ miss-understanding of 
the term exacerbation or their recollection of having an exacerbation [127]. Over-estimation 
could be due to the excessive use of corticosteroids in COPD, used by 70% of patients in 
both Europe and the US, in contrast to the a use of 20% if patients were treated according to 
current guidelines [128]. Although corticosteroids have a slight reductive effect on 
Figure 9: Combined assessment of COPD.  Patients are stratified according to symptoms in the right or 
left column, and, according to lung function and number of exacerbations in the lower or upper row, 
the most severe result of the two assessments determining the patients’ location in the two rows. With 
permission from the GOLD initiative [2].  
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exacerbations (MD -0.26 exacerbations per patient per year), it concurrently increases the 
risk of pneumonias ( RR 1,56) [129]. Pneumonias may be misclassified as exacerbations by 
the clinician and therefore influence COPD disease stratification. which are used by  
 comorbidities: The presence of comorbidities in COPD patients has been shown to increase 
the risk of exacerbations [130], and in the case of exacerbation, the number of comorbidities 
has been shown to be associated with increased risk of hospitalization [131]. The presence 
of comorbidities has also been shown to affect the outcome of the MRC-score. Barr et al. 
showed that in comparable groups of COPD patients, the mean MRC-score increased with 
the number of comorbidities, with a median value of 2.3 in patients who suffered from 1-5 
comorbidities to a median value of 4.0 in patients with 20-25 comorbidities [13]. This is 
further supported by a very recent study that comorbidities, no matter which, significantly 
impair physical activity in COPD independently of airflow limitation [132]. As such 
comorbidities may influence the stratification of the patient. Even though the GOLD 
recommendations 2013 recommends to assess CODP patients’ comorbidities, it has not 
previously been considered to which extent they influence the stratification of the patients 
[2]. 
    The GOLD recommendation suggests treatment dependent on disease severity according to the 
GOLD score. As discussed above it is not unlikely that patient reported outcomes are influenced by 
the presence of comorbidities. As such there is a potential risk of assessing the overall morbidity 
rather than COPD severity when using the GOLD combined risk assessment score, and hence a risk 
of over, or under, treating COPD.  
1.8 Summary: Associations between imaging, clinical and physiological measures in COPD  
In recent years, a number of studies have investigated concomitant clinical and radiological features 
in the endeavour to understand the heterogeneity of COPD. These parameters are often associated 
with physiological measurements as illustrated in Figure 10A. 
Major scientific progress has been made in our understanding of clinical characteristics of COPD 
and the equipment used for the CT-scans continuously improves in speed and resolution. However, 
a similar evolution of pathophysiological measurement has not taken place. Therefore, one may 
speculate: If the easy accessible lung function assessments are insensible to physiological changes, 
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how can we achieve early disease recognition? If lung function measures do not respond to patient 
 
Figure 10: The association between imaging, clinical features and physiological measures in description of lung 
disease (A). Physiological measures as effect modifiers rather than an associated parameter in relation to 
imaging and clinical features (B).  
 
reported outcomes how can we quantify disease progression, unmask the reason for disease 
progression and evaluate treatment? If what is considered pulmonary physiological testing is 
susceptible to the influence of systemic disease, could it not become an effect modifier rather than 
an associated parameter in research, as illustrated in Figure 10B [133]? Given that V̇/Q̇ mismatch 
previously has been argued to be a core pathophysiological change in COPD, should we explore the 
possibilities of other lung function assessments to acknowledge, evaluate and monitor the lung 
component of the disease?  
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Chapter 2: Future perspectives in lung function measurements. 
 
2.1 The automatic lung parameter estimator- ALPE 
As the available tools in the measurement of lung function have limitations, additional assessment 
tools should be sought. A possible tool for measuring pulmonary gas exchange is the Automatic 
Lung Parameter Estimator (ALPE). This method, initially proposed in 2002, uses stepwise changes 
in inspired oxygen fraction (FiO2) and measurement of ventilation and arterial oxygenation at 
steady state for each FiO2 level, along with a mathematical model representation of gas exchange in 
the lungs and tissues illustrated in Figure 11. ALPE enables a bedside description of the pulmonary 
gas exchange properties of the lungs. ALPE has, until recently, primarily been applied in surgical 
patients during controlled ventilation postoperatively [125,126] and in intensive care patients with 
acute lung injury or acute respiratory distress syndrome, where the primary cause of abnormal gas 
exchange is pulmonary shunt and low V̇/Q̇ [134–136]. However, observations from these studies 
indicate that the tool has potential for evaluating spontaneous breathing patients in daily clinical 
care [137–139]. 
2.1.1Mathematical model included in the ALPE 
The ALPE model, shown in Figure 11, describes pulmonary gas exchange using three 
compartments; one compartment representing pulmonary shunt, and two ventilated and perfused 
compartments with uniquely adjustable V̇/Q̇ ratios. The model uses three parameters: fs, the 
fraction of the total cardiac output (Q) not contributing to gas exchange (i.e. pulmonary shunt); f2, 
the distribution of the remaining Q between the two ventilated and perfused compartments; and 
fA2, the distribution of total alveolar ventilation (V̇A) between these compartments. The three 
parameters in the model require steady state measurement at different levels of FiO2. For each level, 
the patient’s response to available oxygen is measured as end tidal oxygen fraction (FetO2) and 
peripheral oxygen saturation (SpO2). Aside from these, the inputs for the model are oxygen 
consumption (V̇O2), obtained from measurement of respiratory gasses, (FetO2 and FiO2), and 
respiratory volumes; Q, either obtained by use of invasive or non-invasive techniques or 
approximated; the acid-base characteristics of blood, which are used to describe the oxygen 
dissociation curve and the V̇A obtained from frequency, tidal volume, and serial dead space (V̇Ds).  
The measurements obtained from the ALPE method are pulmonary shunt, the change in partial 
pressure of oxygen in the blood (ΔPO2,); pulmonary shunt is the fraction of the total Q not 
contributing to gas exchange; ΔPO2 is the model measure of low V̇/Q̇, describing the difference 
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Figure 11: The mathematical model of oxygen transport (from [71] with permission). The model consist of three 
compartments, where two are ventilated and perfused representing gas exchange in the lungs, and the third 
representing pulmonary shunt. The model has three parameters: fs, f2, and fA2; fs: The fraction of the total 
cardiac output (Q) not contributing to gas exchange (i.e. pulmonary shunt). f2: The distribution of the remaining 
Q between the two ventilated and perfused compartments. fA2: The distribution of total alveolar ventilation 
(VA) between these compartments. The equations describe the transport of oxygen at steady state from the a 
ventilator or air into the tissues: 1-4) oxygen flow into the alveoli and blood (VO2) in total and addition from 
each compartment; 5) total expired oxygen fraction (FEO2); 6-7) Oxygen partial pressure (PcO2(1), PcO2(2)) in 
the compartments; 8) drop in O2 partial pressure from expired gas to capillary blood, marked with red circles; 
9) mixed concentration of arterial blood (CaO2); 10-14) relationship between oxygen partial pressure (PO2), 
saturation (SO2) and concentration (CO2) in the capillary compartments calculated from the oxygen dissociation 
curve (ODC) and blood variables; 15-16) concentration of oxygen in the lung capillary compartments (CcO2(1), 
CcO2(2)) combining venous concentration (CvO2) and the increase in oxygen concentration resulting from 
alveolar equilibration; 17) venous oxygen concentration (CvO2) combining arterial oxygen concentration (CaO2) 
and the drop in oxygen concentration as a result of consumption in the tissues [137]. 
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between alveolar FetO2 and capillary blood oxygen pressure (PcO2) leaving the ventilated and 
perfused compartments, i.e. before mixing with the shunted blood. In Figure 11 these measurements 
are highlighted (red circles). In the original publication from 2002, ALPE did not include 
measurement of high V̇/Q̇. This addition to the model was first published by Karbing et al. for use 
in intensive care patients [136].The change in partial pressure of carbon dioxide in the blood 
(ΔPCO2) is the model measure of high V̇/Q̇, e.g. the difference between the alveolar end tidal and 
capillary carbon dioxide pressures. The introduction of ΔPCO2 in ALPE for spontaneous breathing 
patients has further been investigated in a PhD study carried out simultaneously to this, working on 
the technical aspects of using ALPE in COPD [140].  
 
2.1.2 Assumptions included in ALPE 
The ALPE tool applies changes in FiO2 to evaluate pulmonary gas exchange. A number of 
assumptions are included in the model. Some of these have previously been evaluated and some 
require evaluation if ALPE is to be useful as in COPD. The following text describes these 
assumptions, and the state of the art in their evaluation. 
 Oxygen steady state: The ALPE tool describes steady state conditions of oxygen transport, 
where steady state is defined as minimum variations in FetO2. This has been shown to occur 
within 2-3 minutes following a step change in FiO2. A previous study has shown this to be a 
valid assumption for patients without lung disease [141], but in patients with COPD the time 
to steady state following changes in oxygenation is considered to be 20-30 minutes[142] 
based on a 1970’s review [85]. However, the criteria for determining oxygen steady state 
varied substantially between studies, these include 1) the range over which oxygen was 
changed; 2) the direction in which oxygen was changed, i.e. both an increase (wash in) and a 
decrease (wash out) of FiO2; and 3) the definition of the end point for steady state [143–
147]. Therefore, a structured study to determine the time to steady state after changes in 
inspired oxygen in COPD patients is needed. Moreover, monitoring oxygen as therapy to 
COPD patients in daily clinical care, providing knowledge on when sustainable 
measurements can be obtained in patients after having changed FiO2 is also necessary.  
 Hypoxic vasoconstriction: It is well known that a reduction in alveolar O2 induces hypoxic 
vasoconstriction (HPV). HPV has been investigated in numerous studies, which all have 
investigated the effects of large changes in FiO2, resulting in large reductions in alveolar 
oxygen partial pressure [148,149]. HPV caused by changes in FiO2 may result in adverse 
changes in pulmonary pressure. As such, significant changes in pulmonary perfusion 
26 
 
distribution may modify V/Q mismatch. Applying the ALPE model, it is assumed that HPV 
does not occur as the changes in FiO2 are with a limited range. Despite the large number of 
studies examining the effects of oxygen changes on HPV, no previous studies have looked 
at the effect of a small, acute reduction in oxygenation. Neither has the effect on HPV of 
correcting mild, acute hypoxia been investigated. To evaluate the assumption that no 
clinically significant HPV occurs during the ALPE procedure these changes need to be 
investigated. 
To be able to investigate influences of HPV surrogate measures are needed, as HPV in itself 
is not easily monitored; therefore, measures of mean pulmonal arterial pressure (MPAP) and 
pulmonal vascular resistance (PVR) may be used to demonstrate changes.  
 Reference values: In the traditionally lung function measurements reference values are 
dependent on a number of variables, as for example age and gender. The mathematical 
model of ALPE assumes that age, gender and posture do not influence the gas exchange 
parameters. However, it has only investigated in healthy subjects showing that age and 
gender does not influence gas exchange, but that posture did influence the shunt fraction 
[150]. No study in COPD patients exists using ALPE. 
 Reproducibility: It has been assumed that the ALPE measurement is reproducible. In a test-
retest study repeatability was acceptable in healthy subjects [150]. However, studies in 
COPD patients are needed.  
    This thesis focuses on two of these assumptions. The present assumption of time to oxygen 
steady state in COPD differs considerably from the assumption of oxygen steady state in the ALPE 
algorithm. Therefore, investigation of this assumption seems to be crucial for implementing ALPE 
as an assessment tool in COPD. Furthermore, the assumption that the ALPE procedure does not 
cause significant hypoxic vasoconstriction is an assumption, which has not yet been tested. 
Investigating this before considering further application of the method in COPD is therefore 
important.  
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Chapter 3: Hypothesis and aims 
3.1 Hypothesis 
As highlighted in the previous chapter, obtaining a physiological understanding of the patient with 
COPD in clinical practice is a challenging process and new tools for evaluation should be sought.  
    This thesis therefore hypothesises that:  
 The combined GOLD risk assessment score is influenced by the presence of comorbidities 
in COPD patients. 
 The current methods to evaluate physiological lung function do not provide the clinician 
with adequate clinical measure of the pulmonary component in COPD.  
 The assumption behind ALPE related to oxygen steady state is valid in COPD patients. 
 The ALPE examination does not cause significant hypoxic pulmonary vasoconstriction and 
does not therefore influence the underlying physiology to a degree that has impact on 
results. 
3.2 Aims 
The aims of this thesis are therefore: 
1) To investigate the association between the GOLD stratification score and ventilatory 
parameters, in COPD patients with and without comorbidities (study I).  
2) To investigate the clinical association between HR-CT findings, physiological lung 
parameters and the classification of COPD patients with or without comorbidities, (study 
I). 
3) To investigate the association between DLCO, the GOLD stratification score and 
ventilatory- or systemic parameters respectively, (study I and II). 
4) To elucidate the time to steady state in SpO2 and PO2 after changes in FiO2, both in wash 
in and wash out in patients with COPD, (study III). 
5) To investigate the changes in MPAP and PVR as surrogate measures of HPV as 
response to changes in FiO2 (study IV).  
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Chapter 4: Presentation of studies 
4.1 Material 
Four studies constitute this thesis. Data was registered and kept according to the legislation of the 
Danish Data Protection Agency and with approval from the Agency. All patients were informed and 
signed consent according to the Helsinki Declaration. 
 
4.2 Study I 
4.2.1 Study objectives 
Study I: This study was a prospective study, investigating the possible influence of comorbidities on 
the association between the GOLD stratification score and lung function parameters as well as HR-
CT findings of emphysema and airway disease in COPD patients. 
4.2.2 Study population, inclusion/exclusion criteria 
A total of 111 patients were included, of those 106 eligible for the final analysis.  
Patients were included based on  
 Verified COPD, i.e. post-bronchodilator FEV1/FVC < 70 
 Stable state with no exacerbations within 6 weeks prior to examination. 
Exclusion criteria were: 
 Previous lung surgery 
 Other treatment for or suspicion of lung cancer  
4.2.3 Methods 
Patients were examined with high resolution computered tomography (Discovery CT750HD, 
General Electric Company, Fairfield, Connecticut, USA) was performed in accordance with the 
protocol.  
 
Scan type 
Rotation 
time 
Thickness/ 
Image 
interval 
Pitch 
Helical scan 
 
0.5 sec 0.625 mm 0.984:1 
 
Table 1: relevant features of the scan protocol in study 1 
 
Figure 12: Illustration of an axial CT-
scan procedure (A), versus a helical 
scan procedure (B). 
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    An axial scan, Figure 12A, moving both the scanner and the sleigh at the same time, was 
performed, to reduce scan time. The features if the scan are sketched in Table 1. 
    A body plethysmography was performed with MasterScreen® Body (VIASYS Healthcare 
GmbH).and diffusing capacity of the lung for carbon monoxide measured with MasterScreen® PFT 
(VIASYS Healthcare GmbH).  
    For evaluation of the HR-CT scans the approach of Aziz et al. was chosen in combination with 
the reference material published by the COPDGene group [96,151]. Three individuals, two 
radiologists and one pulmonologist, the primary investigator, evaluated the HR-CT scans. The scans 
were prior to evaluation anonymised by a fourth person, who was not otherwise involved in the 
project. Evaluation was performed using the PACS solution (McKesson Radiology™), and as such 
allowed the use of the quantitative tools embedded in this system in combination with qualitative 
evaluation. Before evaluating the HR-CT scans the doctors received a thorough introduction to the 
scoring system accompanied by instruction material, which was available to them throughout the 
evaluation process. The instruction material is available in Appendix 1, although partly in Danish.  
4.2.4 Results 
A significant association between GOLD stratification score was found, and each of the lung 
function parameters: FEV1%, IC% IC/TLC and SpO2 as illustrated in Table 2. These correlation 
coefficients were weakened when patients were stratified to subgroups according to numbers of 
comorbidities. When comparing pairs of variables in patients with 0-1 and 2 or more comorbidities, 
there was a significant difference between GOLD stratification score and FEV1 as well as GOLD 
stratification score and IC/TLC. Furthermore, there was a significant association between 
emphysema grade and lung function parameters as FEV1, IC/TLC, SpO2, (Table 3), as well as 
between emphysema grade the GOLD stratification score in the total study population (p=0.03). 
However, when analyzing subgroups, significant association was only seen between emphysema 
grade and FEV1 in patients with 0-1 comorbidity (p=0.02), as well as emphysema grade and SpO2 
on patients with 2 or more comorbidities, Table 3.  
DLCO was associated with both GOLD stratification score (Table 2) and emphysema grade (Table 
3). Interestingly, the association between DLCO and both of these were not weakened by the 
presence of comorbidities.  
    Unpublished data on correlation analysis between mMRC and lung function parameters showed 
an effect of comorbidities similar to that seen on the correlation between GOLD stratification and 
lung function parameters (Table 4). This may not be surprising, as mMRC is part of the GOLD 
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stratification score; however, mMRC is the patient reported outcome of the score, and could 
therefore well be influenced by other chronic diseases.  
    When hierarchical cluster analysis was applied to the dataset comorbidities clustered with the 
number of exacerbations, the GOLD score and the mMRC score (Figure 12). This further supports 
the associations presented in table 2. 
Table 2: Spearman’s correlation analyses of GOLD-score versus FEV1 in percent of expected value, DLCO in 
percent of expected value, IC in percent of expected value, the ratio between IC and TLC and SpO2 
 
 GOLD score, total study 
population (n=106) 
GOLD score, patients with 
0-1 comorbidity (n=50) 
GOLD score, patients with 2 or 
more comorbidities (n=56) 
 Correlation 
coefficient 
P-value Correlation 
coefficient 
P-value Correlation 
coefficient 
P-value 
FEV1% -0.677 <0.001 -0.805 <0.001 -0.543 <0.001 
DLCO% -0.479 <0.001 -0.475 <0.001 -0.496 <0.001 
IC% -0.584 <0.001 -0.670 <0.001 -0.504 <0.001 
IC/TLC -0.554 <0.001 -0.696 <0.001 -0.426 0.001 
SpO2 -0.327 0.001 -0.387 0.006 -0.315 0.02 
 
 
Table 3: Pearson’s correlation analyses of emphysema grade versus FEV1 in percent of expected value, DLCO in 
percent of expected value, IC in percent of expected value, the ratio between IC and TLC and SpO2 
 
 Emphysema grade, Total 
Study population (n=106) 
Emphysema grade, Patients 
with 0-1 comorbidity (n=50) 
Emphysema grade, Patients 
with 2 or more comorbidities 
(n=56) 
 Correlation 
coefficient 
P-value Correlation 
coefficient 
P-value Correlation 
coefficient 
P-value 
FEV1% -0.281 0.004 -0.418 0.002 -0.138 0.3 
DLCO% -0.454 <0.001 -0.480 <0.001 -0.454 <0.001 
IC% -0.192 0.05 -0.191 0.2 -0.198 0.2 
IC/TLC -0.192 0.04 -0.258 0.07 -0.149 0.3 
SpO2 -0.331 0.001 -0.255 0.07 -0.398 0.002 
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Table 4: Spearman’s correlation analyses of mMRC-score versus FEV1 in percent of expected value, DLCO in 
percent of expected value, IC in percent of expected value, the ratio between IC and TLC and SpO2 
 
 mMRC, Total Study 
population (n=106) 
mMRC, Patients with 0-1 
comorbidity (n=50) 
mMRC, Patients with 2 or 
more comorbidities (n=56) 
 Correlation 
coefficient 
P-value Correlation 
coefficient 
P-value Correlation 
coefficient 
P-value 
FEV1% -0.494 <0.001 -0.598 <0.001 -0.436 0.01 
DLCO% -0.486 <0.001 -0.498 <0.001 -0.471 <0.001 
IC% -0.421 <0.001 -0.425 0.002 -0.409 0.02 
IC/TLC -0.363 <0.001 -0.471 0.001 -0.280 0.04 
SpO2 -0.387 <0.001 -0.368 0.009 -0.405 0.02 
 
 
 
 
 
 
4.2.5 Conclusion 
Study I investigated two of the hypotheses in this thesis and found that the combined GOLD risk 
assessment score was influenced by the presence of comorbidities in COPD patients. Furthermore, 
the current methods to evaluate physiological lung function may not provide the clinician with an 
adequate clinical measure of the pulmonary component in COPD.  
 
Figure 12: Hierarchical cluster analyses of variables of lung function parameters, number 
of comorbidities, number of exacerbations, mMRC score and GOLD score as well as 
grade of emphysema presence of emphysema or airways disease(AD) and both 
emphysema and airways disease. 
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4.3 Study II 
4.3.1 Study objectives 
This study was a retrospective study investigating whether DLCO is predictive of respiratory 
impairment in COPD, described by measurements of O2 and CO2, and whether DLCO is associated 
with the GOLD stratification score. 
4.3.2 Study population, inclusion/exclusion criteria  
Fifty patients were included retrospectively in the second study, all eligible for final analysis.  
Patients were included based on  
 Verified COPD, i.e. post-bronchodilator FEV1/FVC < 70 
 Stable state with no exacerbations within 6 weeks prior to examination. 
Exclusion criteria were: 
 Previous lung surgery. 
 Other treatment for or suspicion of lung cancer 
4.3.3 Methods 
Diffusing capacity of the lung for carbon monoxide measured with MasterScreen® PFT (VIASYS 
Healthcare GmbH). Furthermore oxygen saturation at FiO2 = 0.21 and =0.15 was investigated, 
mediated by ALPE® Essential (Mermaid Care, Nr.Sundby Denmark). 
4.3.4 Results 
DLCO% was associated to the GOLD stratification score (R2= 0.42, p<0.001). The regression 
equation describing this being: 
DLCO%=69-(10*GOLD) 
However, the association found between DLCO% and the GOLD stratification score was 
strengthened when controlling for BMI, haemoglobin and glucose, (R2=0.58, p<0.0001), with the 
multiple regression equation describing the influence of the different components on the diffusion 
capacity being:  
DLCO% = 56 + (-0.6*GOLD) + (0.6*BMI) + (1.5*haemoglobin) – (2*Glucose). 
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These parameters were chosen by forward selection. The initial analyses also included investigation 
of the association between DLCO% and smoking status and number of pack years, which were non-
significant and did not qualify for inclusion in the multiple regression analysis. 
    There was a weak but significant association between DLCO% and SpO2 at room air, (R
2=0.25, 
p= 0.001) and a significant association between DLCO% and ΔCO2 (end tidal PCO2- arterial 
PCO2), (R
2=0.16, p= 0.03). Multiple regression analysis showed weak association between 
DLCO%, SpO2
 at room air, SpO2 at FiO2=0.15 and ΔCO2, (R2=0.3, p=0.03) with the regression 
equation describing the influences of the different components as follows: 
DLCO%= -277 + (5.5* SpO2
21) - (2.2*SpO2
15) - (2.8*ΔCO2). 
4.3.5 Conclusion 
Study II investigated the second hypothesis in this thesis and further supported that the current 
methods to evaluate physiological lung function do not provide the clinician with an adequate 
clinical measure of the pulmonary component in COPD. 
 
4.4 Study III 
4.4.1 Study objectives 
This study was a prospective study, investigating the time to oxygen steady state after decrease as 
well as increase in inspired oxygen in patients with very severe COPD and chronic respiratory 
failure. 
4.4.2 Study population, inclusion/exclusion criteria  
Fourteen patients were included, with 12 eligible for final analysis. 
Patients were included based on  
 Verified COPD, i.e. post-bronchodilator FEV1/FVC < 70 
 Need of treatment with long term oxygen therapy (LTOT), all for more than 1 year prior to 
inclusion 
 Stable state with no exacerbations or major changes in treatment of comorbidities within 6 
weeks prior to examination. 
Exclusion criteria were: 
 Previous lung surgery 
 Other treatment for or suspicion of lung cancer 
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4.4.3 Methods 
Wash-out of supplementary oxygen was performed by removing nasal cannula providing 1-4 
litres/minute of supplementary oxygen to patients; arterial blood samples were drawn at the time of 
removal and after 1, 2, 4, 8, 12, 17, 22, 32 and 34 minutes. Oxygen wash-in was performed by 
reinserting nasal cannula with the prescribed amount of oxygen. Arterial blood samples were drawn 
as cannula were reinserted and after 1, 2, 4, 8, 12, 17, 22, 32 and 34 minutes. Arterial blood was 
drawn in PICO50® syringes (Radiometer, Copenhagen, Denmark), and analysed to obtain blood 
gas- and acid-base status (ABL 835 and 837, Radiometer, Copenhagen, Denmark). 
 
 
 
 
 
 
Figure 13: Examples of titration curves for oxygen wash-out over 34 minutes, demonstrating partial 
pressure, PO2 ( mmHg) and oxygen saturation, SO2(fraction) in COPD patients in need of LTOT 
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4.4.4 Results 
Oxygen equilibration relevant for clinical interpretation requires 10 minutes following oxygen wash 
in and 16 minutes following oxygen wash out in patients with COPD in need of LTOT [152]. 
Examples of titration curves are demonstrated in figure 13.  
 
4.4.5 Conclusion 
Study III investigated the third hypothesis of this thesis. As the assumption behind the ALPE is that oxygen 
steady state is obtained within 2 minutes this assumption proved invalid in COPD patients.  
4.5 Study IV 
4.5.1 Study objectives 
This study was a retrospective study, investigating whether mild hypoxia induced by changes in 
inspired oxygen causes hypoxic pulmonary vasoconstriction (HPV) and if so, whether these 
changes are reversed when inspired oxygen is returned to initial values. MPAP and PVR were used 
as surrogate measures of HPV.  
4.5.2 Study population, inclusion/exclusion criteria  
In the original protocols, 65 patients were included, with 42 eligible for inclusion in this study.  
Patients were included based on  
 Need of elective coronary artery bypass grafting  
 Investigation with the ALPE system 4 hours post-operatively  
 Ventricular ejection fraction >0.40 
Exclusion criteria were 
 Concomitant valve disease, atrial fibrillation or flutter  
 Chronic dialysis treatment 
 Treatment for lung disease 
4.5.3 Methods 
Patients in study IV were all monitored with a pulmonary arterial catheter (continuous cardiac 
output, Edwards Life sciences, Irvine, CA, USA). The catheter was inserted in either the internal 
jugular vein or the subclavian vein and forwarded through the superior caval vein and into the right 
atrium. From here, it was further wedged into a medium sized branch of the pulmonary artery in 
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order to be able to measure the pulmonary artery wedge pressure (PCWP). Besides this procedure, 
MPAP, cardiac output (CO), central venous pressure and mixed venous saturation was measured.  
PVR was calculated as  
(MPAP – PCWP)/ CO*80 (dyn·s·cm−5) 
4.5.4 Results 
In study IV a 4 mmHg increase in MPAP and a 41 dyn·s·cm−5 increase in PVR was seen in 
response to a reduction in FiO2 of 0.20. There was no difference in patients with initial MPAP both 
above and below/equal to 25 mm Hg, i.e. patients with initially increased or normal pulmonary 
pressure. The increase in MPAP and PVR was shown to be immediately reversible on returning 
FiO2 to baseline or higher values.  
Figure 13A illustrates a typical response of MPAP to changes in FiO2. Figure 13B illustrates a 
response of PVR to changes in FiO2 as seen in the majority of patients.  
 
Although the study population for this study was not COPD patients but patients with ischemic 
heart disease an unpublished sub-analysis was made in patients with a smoking history, 
demonstrated in table 5 and 6. There was no significant difference in changes in MPAP and PVR in 
patients with- and without a smoking history. 
 
 
 
Figure 13: Typical responses in mean pulmonary arterial pressure (MPAP) (A) and pulmonary vascular 
resistance (PVR) (B) in response to changes in FiO2 
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Median [quartile] 
           (number) 
Median MPAP, mm 
Hg 
Variability in  MPAP 
during study period, 
mm Hg 
Difference in MPAP, (mm Hg), 
initial value – value at FiO2 
increase 
Smokers and former 
smokers (27) 
23.0 
[21.3-25.5] 
 
4.0 
[3.0-5.0] 
 
0.0 
[(-1.0)-0.0] 
 
Never smokers (12) 24.3 
[22.6-26.3] 
 
3.5 
[3.0-5.3] 
 
0.0 
[(-0.25)-1.0] 
 
 
Table 6: Subgroup analyses in never smokers and former or present smokers (median 35 pack years) of the 
pulmonary vascular resistance (PVR), the variability of PVR during the study period and the difference between 
PVR before decreasing FiO2 and after having returned FiO2 to initial or higher values  
Median [quartile] 
           (number) 
Median PVR, 
dyn·s·cm−5 
Variability in  PVR 
during study period, 
dyn·s·cm−5 
Difference in PVR, dyn·s·cm−5, 
initial value – value at FiO2 
increase 
Smokers and former 
smokers (27) 
 
117.6 
[86.4-144.0] 
 
53.6 
[40.8-77.6] 
1.6 
[(-8.8)-15.2] 
Never smokers (12) 
120.8 
[101.6-160.0] 
 
85.6 
[57.6-91.2] 
(-7.2) 
[(-16.8)-13.6] 
 
 
4.5.5 Conclusion 
Study IV studied a general, not yet investigated assumption behind the ALPE model, which was the 
fourth hypothesis of this thesis. The ALPE examination does influence the underlying physiology 
but not to a degree, that has impact on results.  
 
 
  
 
 
 
 
Table 5: Subgroup analyses in never smokers and former or present smokers (median 35 pack years) of 
the median pulmonary arterial pressure (MPAP), the variability of MPAP during the study period and 
the difference between MPAP before decreasing FiO2 and after having returned FiO2 to initial or higher 
values  
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Chapter 5: Discussion 
In this chapter, the aims of the thesis are discussed in consecutive numbers 1-5. In connection with 
the aims, the methodological considerations of the papers that investigate the aims are discussed. 
5.1 First aim 
The first aim was to investigate the association between the GOLD stratification score and lung 
function parameters in COPD patients with and without comorbidities. This was investigated in 
study I, where the main findings were an association between GOLD score and FEV1%, IC% 
IC/TLC and SpO2, which was weakened by the presence of comorbidities. These findings were 
supported by a significant difference between GOLD score and FEV1 as well as IC/TLC between 
subgroups with and without numerous comorbidities. The influence of comorbidities on the 
outcome of the GOLD score is further supported by the clustering between comorbidities and 
GOLD score in the cluster analysis (study I).  
5.1.1 Methodological considerations 
Study I was based on two prospective studies with a total of 106 participants. This was a pilot 
study, reflected by the size of the study population. This may influence whether the study 
population was representative of COPD patients in general. Given the distribution of comorbidities 
in this group, compared to previous studies [16,24] it would be reasonable to consider the included 
patients representative of COPD patients in general. Furthermore, the size of the population may 
weaken the correlation analyses between subgroups. However, as significant differences are seen in 
the two key areas, which support the hypothesis, the results are considered valid. Furthermore, these 
are strongly supported by the hierarchical cluster analysis. 
    The choice of variables in study I is a matter for discussion. IC and IC/TLC were chosen as 
measures of hyperinflation. An alternative measure could have been the forced residual capacity. 
However, IC/TLC is often used to describe static hyperinflation and as such, this measure applied to 
this study population, which was examined at rest under steady state conditions. A six-minute 
walking test would possibly have been an interesting measure to evaluate. However, a six-minute 
walking test elucidates the consequences of pathological changes during exercise, but does not 
expose the underlying pathology. At rest this can be expressed by SpO2. Therefore, SpO2 was 
chosen in this study population.  
    The GOLD score is used to stratify COPD patients to treatment regimens worldwide. It is a 
composite measure that includes evaluation of patients’ symptoms that may be done using different 
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scoring systems. In study I one of the three scoring systems recommended by GOLD was used to 
evaluate patients’ symptoms [2]. The results of this study may therefore not be representative if 
other scores were used in the GOLD stratification. However other symptom scores such as the 
COPD assessment score, has been proven to be comparable to the mMRC score [153], and 
therefore the choice of a single evaluation score appears to be valid. 
    Patients were recruited after public announcement at the outpatient clinic at Aalborg University 
Hospital as well as at local the rehabilitation centre. This approach was chosen to get a broad 
representation of COPD severity in the study population. However, this recruitment approach 
includes a risk of selection bias, as these patients all had approached the health care system and 
therefore showed abilities of self-care. Other types of selection bias may also be present – either, 
patients with less severe COPD may have the energy to participate in a study – or the most 
symptomatic patients choose to join in order to be examined thoroughly.Therefore, they may not be 
representative of the entire population of COPD patients. However, the distribution of COPD 
severity is very consistent with that found in previous studies [123,154].  
5.1.2 Interpretation of results 
The significant associations shown in study I are consistent with the results of previous studies 
[122,155]. Previously, significant associations have been shown between longitudinal changes in 
the GOLD stratification score and FEV1, SpO2 and IC, in the ECLIPSE and the UPLIFT studies 
[122,155].These findings show that the GOLD stratification score is a valid measure of the 
physiological changes in COPD. However, study I indicated that the association between GOLD 
stratification score and lung function parameters may be influenced by the presence of 
comorbidities. The ECLIPSE study is not a population based study and therefore sampling bias 
cannot be excluded [121]. The UPLIFT study has been criticized for excluding patients with 
comorbidities [156]. Even though Study I is not a population based study, which would have been 
ideal, the number of comorbidities in the study population is comparable to the studies from the 
groups of Garcia-Olmos and Divo, discussed previously in this thesis [16,24]. The findings of study 
I could therefore indicate that patients with comorbidities should be included in future studies. This 
should be done to ensure that results could be generalized to the COPD population. Since the 
presence of comorbidities is important to the classification of the severity of COPD, it may be 
important to distinguish whether an increased severity is due to worsening pulmonary disease or 
comorbidities. As discussed below, current clinical tools for measuring changes in pulmonary 
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pathophysiology have limitations, and in particular the use of FEV1 in the GOLD score. It may 
therefore be important to consider new, more specific tools. 
    The GOLD stratification score was implemented to strengthen the evaluation of disease severity 
in COPD. Prior to the introduction of the GOLD stratification score the assessment of COPD relied 
heavily on FEV1. However, as stated by the GOLD group, FEV1 is of limited value in evaluation 
of COPD severity and reflection of symptoms [2]. This was elaborated by the ECLIPSE study 
group, who concluded that FEV1 does not capture the heterogeneity of the disease [121]. 
Furthermore, data from the TORCH study showed that the change in quality of life was independent 
of changes in FEV1 [157]. Therefore, the 2013 interim revision of the GOLD recommendation 
included the composite measure of patient reported outcomes and FEV1 [2]. Today the GOLD 
stratification score is the gold standard for evaluation of COPD severity. However, data from study 
I suggest that the GOLD stratification score seems to be influenced by the presence of 
comorbidities. This could indicate that the GOLD stratification score may measure morbidity in 
general rather than COPD severity. If this is the case, one could consider using existing lung 
function parameters, such as the IC, the IC/TLC and SpO2, to supplement the existing score, in 
order to understand the underlying pulmonary pathology.  
    IC and the ratio IC/TLC are measures of hyperinflation and have been shown to be strongly 
associated with dyspnea [46,50]. As dyspnea is a central feature of COPD these could be 
appropriate to include in the evaluation of the patient. However, the measurements require a body 
plethysmography, which is not easily accessible in primary and secondary care, let alone in 
developing countries. Moreover, it is expensive equipment dependent on a stable surrounding 
environment and specialized technical support in order to obtain valid and reproducible results. 
Furthermore, it requires operation by trained and experienced personnel to obtain valid 
measurements.  
    In contrast, SpO2 is easy to measure, does not require trained personnel, and the equipment for 
measuring is inexpensive. It is well known that a need for LTOT increases mortality [158,159], but 
otherwise studies investigating SpO2 in stable state as a predictor of mortality has shown conflicting 
results [32,47,159]. However, previous studies have shown low SpO2 to be a risk factor for 
readmission to hospital after an exacerbation of COPD [160]. In addition, a number of smaller 
studies have indicated that exertional desaturation is related to a poorer prognosis in COPD. 
However, different definitions of desaturation and different modes of exercise makes it difficult to 
compare these studies [161]. Hence, the clinical consequence of decreased SpO2 in COPD is not 
fully understood. Moreover, SpO2 is the result of pathological changes, but does not unmask the 
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underlying pulmonary pathology; one could dare to say – this may also be the case for GOLD 
stratification score.  
    In summary, if COPD patients have comorbidities they may be stratified to a higher stratum than 
COPD severity would require. This may lead to over treatment of COPD. In contrast, if too much 
impact is put on the GOLD stratification score, comorbidities could be masked and thereby under-
diagnosed. As of today the available tools do not provide the clinician a strong support in 
distinguishing between pulmonary pathology and comorbidities in COPD, yet there is a need to 
focus on both. Hence, an easy accessible, inexpensive and easy applicable alternative tool for 
measuring COPD would be welcomed.  
5.2 Second aim 
The second aim of this study was to investigate the clinical association between HR-CT findings, 
lung function parameters and the GOLD stratification score of COPD patients with or without 
comorbidities. This was investigated in study I, where the main findings were a significant 
association between emphysema grade and lung function parameters as FEV1, IC/TLC, SpO2, as 
well as between emphysema grade the GOLD stratification score in the total study population. 
However, when analyzing subgroups, significant association was only seen between emphysema 
grade and FEV1 in patients with 0-1 comorbidity, as well as emphysema grade and SpO2 on 
patients with 2 or more comorbidities.  
5.2.1 Methodological considerations 
Methodological issues relating to study I have been discussed in connection with the first aim. 
However, considerations concerning the choice of method to evaluate the HR-CT scans apply to the 
third aim of this thesis.  
    A number of limitations should be considered in connection with evaluation of the CT-scans. As 
previously discussed in this thesis, it is debatable which choice of method is superior for describing 
HR-CT scans. In a qualitative approach such as visual scoring, inter-observer variability in the 
interpretation exists. However, large groups as the COPDGene group and Dirksen and colleagues 
both consider the inter-observer variability to be acceptable and consider visual scoring a reliable 
method for interpreting especially emphysema in CT scans [96,162]. The choice of method in 
relation to describe clinically relevant findings has also been debated previously [151,163] These 
obstacles have been considered when designing study I. For the analysis performed in study I, the 
decision as to the selection of the CT-evaluation technique was inspired by two groups, one that has 
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provided a validated reference material for visual scoring of CT scans and another that has 
considered the association between radiological and clinical manifestations of the disease [96,151]. 
Both these considerations were implemented to minimise inter-observer variability and also to 
accommodate the planned correlation analysis with lung function parameters. Thus, the inter-
observer agreement found in study I expresses both the presence of emphysema and airways disease 
with values comparable and even superior to the results of previous studies [85,96,162]. 
Furthermore, associations between HR-CT findings and lung function parameters were seen in 
study I. These observations concerning the choice of method should be carried forward to future 
studies.  
5.2.2 Interpretation of results 
Previous studies have shown a significant association between emphysema grade and FEV1 
[57,164], which is consistent with the findings of study I. An association between emphysema and 
hyperinflation has also been shown previously [57], which is consistent with the association 
between emphysema and IC/TLC shown in study I. Moreover, a negative association between 
emphysema grade and SpO2 shown by Fujimoto et al. [165] is also similar to that shown in study I. 
A single paper from the COPDGene group has shown greater extent of emphysema and more gas 
trapping in higher GOLD strata than in lower GOLD strata [166], which is also consistent with the 
findings in study I. These findings suggest that the study population might be generalised to 
represent other COPD populations.  
    When analysing subgroups, study I showed a significant association between emphysema grade 
and FEV1 in patients with 0-1 comorbidities but no association when analysing patients with 2 or 
more comorbidities. Literature is sparse on the influence of comorbidities on the association 
between emphysema and lung function parameters, but a single study showed no association 
between FEV1 and emphysema in heart disease [167]. One could suspect that the association of 
lung function parameters would be independent of the influence of comorbidities, but in general, 
this does not seem to be the case when considering the results from study I. A possible explanation 
could be that systemic inflammation in patients with numerous comorbidities has an impact on 
either the degree of emphysema or the outcome of lung function parameters, but further studies are 
required to test this postulate. 
    Surprisingly, a rather strong association was seen in paper 1 between emphysema grade and SpO2 
in patients with numerous comorbidities, whereas no association was seen in patients with 0-1 
comorbidity. To this author’s knowledge, this has not been described previously. One could 
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speculate whether SpO2 reduction is a result of impaired pulmonary perfusion and that this 
impairment may be reinforced by the presence of comorbidities. However, this would be a subject 
for future research, as described in chapter 5. 
    Finally the subgroup analysis in study I showed a significant association between emphysema 
grade and GOLD stratification score in patients with 0-1 comorbidity but no association in patients 
with 2 or more comorbidities. This thesis has suggested that the GOLD stratification score 
demonstrates overall morbidity in COPD patients. As COPD causes major morbidity, as shown by 
many authors, [168] the association in the subgroup with 0-1 comorbidity was not unexpected. The 
fact that there is no association between emphysema grade and GOLD stratification score in 
patients with numerous comorbidities may support further the hypothesis that the GOLD 
stratification score does not relate specifically to lung disease 
    In summary, two messages with possible clinical implications can be concluded from the results 
of study I. 1) both emphysema or lung function parameters could be influenced by the presence of 
comorbidities. This should be investigated further in future as it may influence our evaluation of 
these patients. This is further discussed in chapter 5. 2) a decrease in SpO2 may be a result of the 
impairment of pulmonary perfusion, which forces us to consider more than the broncho-alveolar 
system when we as clinicians evaluate respiratory insufficiency. However, this also needs to be 
investigated further in future studies.  
 
5.3 Third aim 
The third aim was to investigate the association between DLCO, the GOLD stratification score and 
ventilatory- or systemic parameters respectively. This was investigated in study I and II, where the 
main findings were a significant association between the GOLD stratification score and DLCO. 
Furthermore, study I indicated that the association between the GOLD stratification score and 
DLCO was not influenced by the presence of comorbidities. In addition, study II showed weak 
association between DLCO and respiratory parameters as the outcome of changes in FiO2 and 
differences in arterial and end-expiratory CO2, in contrast to a strong association between DLCO 
and systemic parameters. 
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5.3.1 Methodological considerations 
Both results from study I and II are included in the discussion of the second aim. As the 
methodology of study I is discussed above, this section will focus on considerations concerning 
study II. 
    Study II was a retrospective study based on patients from a protocolled study as well as patients 
from a feasibility project carried out in the department. As such, this limited the size of the study 
population. Furthermore, there were a number of missing values, which could not be obtained 
retrospectively. Moreover, being retrospective, the study could not be designed to investigate the 
message from the systemic parameters thoroughly, i.e. glucose levels as well as BMI were within 
normal ranges in the study population. As such, future study should be designed to consider the 
impact of systemic parameters, as described in chapter 5. 
 
5.3.2 Interpretation of results 
DLCO is a very interesting measure in pulmonary physiology, thought to describe the diffusion 
properties of the lungs. However, it has previously been demonstrated that the primary problem 
associated with gas exchange in COPD is not diffusion limitation [169]. Instead, the primary 
problem is V̇/Q̇ mismatch, with heterogeneous distribution of both areas of high, i.e. areas with 
impaired perfusion, and low, i.e. impaired ventilation, V̇/Q̇ ratios are seen in the lung [74,169]. In 
study II a weak association is seen between DLCO and SpO2 measured at FiO2 = 0.21, as well as 
other markers of respiratory disease, such as SpO2 measured at FiO2= 0.15 and ΔCO2, are not 
associated with DLCO. This is consistent with physiological knowledge about V̇/Q̇ mismatch, 
described above. 
    Previously an association has been shown between emphysema grade and DLCO [57], which is 
also consistent with the findings in study I. Furthermore, DLCO has been associated with dyspnea 
in COPD [59,170,171] and an association between DLCO and mMRC was also seen in unpublished 
data from study II. Interestingly, DLCO has also been associated with dyspnea in heart disease 
[171] and, in a single study, in diabetes patients [172]. However, several authors have found a faster 
longitudinal decline in DLCO in diabetes patients compared to otherwise comparable non-smoking 
non-diabetics [172], explained by development of micro-angiopathy in the diabetic lung. In study II 
systemic markers as glucose level and BMI were associated with DLCO when performing multiple 
regression analysis. Therefore, it is interesting to speculate whether DLCO might be a good 
descriptor of systemic deconditioning instead of a descriptor of pulmonary gas exchange. The 
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speculation may seem irrational, given that DLCO is measured by inhalation. However, the 
explanation could be as follows: If DLCO was to be an adequate representation of V̇/Q̇ 
abnormalities it would need to describe changes in ventilation and perfusion sufficiently. The 
standard method for measuring DLCO involves breath holding at maximal inspiration. This means 
that the amount of CO diffused is more likely to reflect maximal inspiratory volume than the 
individual’s normal ventilation. Indeed, it could be postulated that maximal inspiration may 
increase gas volume in all regions of the lung, potentially normalizing low V̇/Q̇ regions and 
increasing gas exchange abnormality in regions with high V̇/Q̇. In contrast, the amount of CO 
diffused may be highly affected by changes in perfusion and blood hemoglobin-concentration, as 
previously reported by other authors [75,173]. As pulmonary perfusion changes are seen in 
systemic diseases as diabetes [172,174], chronic heart failure [175]as well as in COPD [176,177], 
this could lead to the thought that DLCO may reflect systemic changes, without correlating with 
oxygen and carbon dioxide levels. 
    In summary, we may need to re-consider what DLCO measures and how to use it. It is 
noteworthy to find one measure very closely associated to a composite measure as the GOLD 
stratification score. If the GOLD stratification score reflects the overall morbidity of the COPD 
patient, DLCO may be an objective measure of systemic deconditioning in COPD, which allows us 
to monitor the deterioration of the COPD patient over time. However, it is important to note that 
abnormal values of DLCO are not only present in patients with COPD but in patients with high 
morbidity in general. 
    DLCO has in clinical care been used to evaluate the gas-transfer abilities of the lung. If DLCO is 
not specific to the lung, this leaves us with another challenge; how do we measure gas exchange in 
COPD? A new tool to meet this challenge would be welcomed.  
5.4 Fourth aim 
The fourth aim of this thesis was to elucidate the time to steady state in SpO2 and PO2 after changes 
in FiO2, both for oxygen wash in and wash out in patients with COPD. This was investigated in 
study III, where the main results were that oxygen equilibration relevant for clinical interpretation 
required 10 minutes following oxygen wash in and 16 minutes following oxygen wash out in 
patients with COPD in need of LTOT treatment. 
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5.4.1 Methodological consideration 
Study III was a prospective study on a small group of patients. The size of the study population is 
therefore a limitation to this study. However, despite some inter-personal variation, steady state in 
both oxygen partial pressure and oxygen saturation in consecutive tests was seen in the entire study 
population suggesting that the results are valid. The study participants were all very severely ill 
COPD patients with chronic respiratory failure in need of LTOT; none of the patients were alive at 
the time the study was published. Therefore, the results may not be generalized to the COPD 
population. However, by choosing the most severely ill patients for the study population, the results 
could be thought of as “worst case scenario” meaning that more healthy patients are likely to reach 
oxygen steady state at least as fast as the study population.   
Patients were all stable at the time of inclusion. Therefore, the results of this study may not be 
applicable in COPD patients with exacerbations.  
    The choice of end point in study III is a matter for discussion. Previous studies have used either 
return to exact steady state or the time to reach 90% of the final value (T90). Moreover, T90 suffers 
from the fact that it is variable in the same individual, dependent on the increment of the oxygen 
step. Reaching both of these endpoints is time consuming and the results do not have any relevance 
for clinical decision-making. For clinical interpretation study III suggests that reaching within 1% 
of the final oxygen saturation is adequate.  
    Patients were invited by public announcement in the outpatient clinic at Aalborg University 
Hospital. Nevertheless, they were all well known to the author and chose to participate despite no 
financial compensation, the enormous physical effort it took them to get to the investigation site and 
risk of discomfort due to hypoxia that the study imposed on them. Therefore, there may be both a 
selection bias and a case of excessive compliance in this study. However, as blood gasses are very 
objective measures this is unlikely to influence the time to steady state of oxygen in these patients. 
5.4.2 Interpretation of results 
    Oxygen steady state is obtained within 2 to 3 minutes of changing FiO2 in healthy individuals 
[178]. The “American Thoracic Society/European Respiratory Society standards for diagnosing and 
treatment of COPD” contains recommendations for monitoring oxygen during an exacerbation of 
COPD. In this standard the authors recommend to monitor PaO2 with 1-2 hours intervals [179]. 
Until now, recommendations for monitoring oxygen changes in COPD are based upon a review 
published by Woolf in the 1970’ies. This paper concluded that 30 minutes should be waited before 
measuring PaO2 after changes in FiO2 [142]. However, since the studies cited by this review were 
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not easily comparable this conclusion could be questioned. The studies included all assess changes 
in FIO2, and monitor the subsequent changes in oxygenation in arterial blood in COPD patients. 
However, the variables chosen to describe the response to oxygen changes were not consistent, with 
either PaO2 [143,144], or SpO2 [147] used to evaluate steady state. Studies did not investigate both 
decrease (oxygen wash out) and increase (oxygen wash in) in FiO2. As such, studies in 
spontaneously breathing patients only considered oxygen wash out [143,144,146,147] and a single 
study in mechanically ventilated patients only considered oxygen wash in [145]. Moreover, 
previous studies used different sampling times. Only one study measured PaO2 frequently enough 
in the early phase to elucidate the fast dynamics of oxygen changes [144]. Furthermore, the end 
point for the oxygen change were analyzed in different ways for different studies, with some using 
return to baseline [143,144], and others T90 [145,146]. Finally, none of the studies were performed 
within ranges of FiO2 relevant for daily clinical practice, with studies typically changing FiO2 from 
room air (21%) to 100%. In contrast, study III 1) measures both wash out and wash in of oxygen, 2) 
measures both SpO2 and PaO2 and with sample times that allow description of the fast dynamics of 
oxygen immediately after changing FiO2 and 3) operates within a clinically relevant range of FiO2. 
This serves two purposes: To make the study relevant for clinical practice and to challenge the 
assumption behind the ALPE method. 
    In daily clinical practice the findings of study III mirror clinical observation of the COPD 
patients in need of LTOT, as steady state is obtained within a quarter of an hour opposing the half 
an hour suggested by Woolf. If this finding can be generalized to the entire COPD population this 
may change the monitoring procedure in patients in LTOT treatment in the future. 
    Based on studies in healthy individuals it has been assumed that oxygen steady state is obtained 
within few minutes during the ALPE measurement [180]. However, study III shows that steady 
state was obtained after a maximum of 16 minutes in COPD patients. Hence, the assumption behind 
the ALPE method is not met in these patients. One could therefore argue that the ALPE system 
should not be used in COPD; new, alternative methods, as the micropore membrane inlet mass 
spectrometry exists for MIGET [181], which facilitates the procedure. However, it is still a complex 
and time-consuming procedure compared to ALPE. Even though the ALPE method needs revision 
before the system is clinically applicable in COPD patients it could potentially be useful due to its 
simplicity in daily clinical care. The revision has been approached by a new algorithm which 
evaluate patients’ breath-by-breath changes in respiratory and blood oxygenation [182,183]. This 
algorithm, presented in a recent PhD study [140], has proved promising as an alternative to the need 
for oxygen steady state in the ALPE method.  
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    In summary, the assumption behind the ALPE that oxygen steady state is obtained within a few 
minutes does not apply for patients with very severe COPD and therefore needs reconsideration if 
the method is to be considered in the assessment of lung function in COPD en future.  
 
5.5 Fifth aim 
    The fifth aim of this thesis was to investigate the changes in MPAP and PVR, as surrogate 
measures of HPV, in response to changes in FiO2. This was investigated in Study IV, where the 
main results were a 4 mmHg increase in MPAP and a 41 dyn·s·cm−5 increase in PVR in response to 
a reduction in FiO2 of 0.20. The increase in MPAP and PVR was shown to be immediately 
reversible on returning FiO2 to baseline or higher values. 
5.5.1 Methodological considerations 
Study IV was a retrospective study on a highly selected study population. As such, this limited the 
number of participants in the study. Furthermore, there were a number of missing values, which 
could not be obtained retrospectively. Moreover, it would have been desirable if information on the 
pulmonary condition of this population had been available. In the original study design patients 
with signs of severe lung disease were excluded, but given substantial tobacco consumption and the 
similarity in symptoms between ischemic heart disease and COPD, it is not unlikely that a number 
of the study participants suffered from both. As such a spirometry measurement, data on mMRC-
score and exacerbations would have been helpful to diagnose and stratify COPD. These, along with 
preoperative values of PCO2 would have been of interest to elucidate the possible risk of respiratory 
failure.  
    This highly selected patient group may not be representative of all critically ill patients, not least 
spontaneously breathing patients where it has been suggested that mechanisms of HPV differ from 
those in mechanically ventilated patients [184]. However, this patient group remains very 
interesting. All study patients had undergone cardiac surgery 4 hours prior to the examination, 
which induces cardiac stunning; furthermore, they were all treated with beta blockers and paced. As 
such, one would expect the cardiac response to remain unaltered and to rise only if peripheral 
ischemia occurs. This provides a unique opportunity to study the isolated effect of changes in 
oxygenation on the pulmonary circulation.  
    The use of MPAP and PVR as surrogate measures of HPV have been used by many previous 
authors [148,185]. This is due to measurement of HPV being very difficult and virtually impossible 
in vivo. Changes in MPAP as an evaluation of HPV have therefore been used since Euler et al. 
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recognized an increase in MPAP without concomitant increase in right atrial pressure in response to 
hypoxia, and hereby started what could be called “modern observations of HPV in vivo” [149]. 
Only shortly after this Borst et al presented a method to measure PVR, which is now often used to 
supplement MPAP in elucidating HPV [186]. As such, MPAP and PVR can be considered valid 
surrogate measures of HPV. 
5.5.2 Interpretation of results 
Both in healthy persons and patients with chronic heart failure, coronary heart disease and in 
chronic obstructive lung disease, MPAP has been shown to rise 13-21 mmHg during mild, 
clinically advantageous exercise [187–190]. The finding in study IV of an increase in MPAP of 4 
mmHg can therefore be considered small. Similarly, in the clinical setting, PVR is expected to 
increase 50-300% in response to HPV [185]. In comparison to these observations, the change in 
PVR of 35% in study IV is small. However, in contrast to patients in a clinical setting, the cardiac 
response of the study participants was virtually eliminated and therefore only a HPV response was 
seen. Another explanation could be that only mild hypoxia was induced on the study population in 
study IV and therefore only very mild HPV occurs. 
    In previous studies, larger changes in oxygenation have been carried out. Hambreus-Johnsen et 
al. showed, that when switching from ventilating both lungs at FiO2 = 1.00 to ventilating one lung 
at 1.00 and the other at 0.12, the blood flow to the hypoxic lung decreased only 5% [191]. 
Furthermore Marshall et al. simulated only small changes in pulmonary shunt when varying FiO2 
within a range of 0.3 to 1.0 [192,193]. As oxygen changes were considerably larger in these studies 
compared to that of study IV, the minor change in MPAP and PVR were not surprising. 
    In study IV both MPAP and PVR return to baseline values in response to restoring oxygenation. 
This probably indicates that only minor vasodilatation occurs. Literature on the effect of hyperoxia 
have shown conflicting results, with some showing signs of vasodilatation [194,195], other showing 
no change [194,196,197] and some even advocating risk of vasoconstriction [198–200]. Fineman et 
al., when changing oxygenation from room air to 100%, indicated that vasodilatation does not occur 
in healthy individuals, but does occur in patients with pulmonary disease [194]. A possible 
explanation is that in healthy individuals, breathing room air, there is no HPV in contrast to patients 
with pulmonary disease. In line with this the minor vasodilatation seen in study IV can only be seen 
when patients have had preceding HPV. Only a group of 5 patients with severe anemia 
(Hemoglobin ≤5 mmol/l) did not return either MPAP or PVR to baseline after oxygenation was 
restored. This could advocate that caution should be taken when performing the ALPE procedure on 
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patients with severe anemia; however, further studies are needed to investigate the effect of mild 
hypoxia in patients with anemia.  
    In summary, the relatively small changes in MPAP and PVR seen in this study indicate that only 
mild HPV occurs in response to mild hypoxia induced in the patients during an ALPE procedure. 
From a clinical perspective, knowledge about a mild increase in MPAP and PVR and not least that 
correcting mild hypoxia has an acute positive effect on MPAP and PVR may be of use to the 
anesthesiologist. An example of this could be in intensive care, where the anesthesiologist often 
changes FiO2 in mechanically ventilated patients. In terms of the ALPE procedure, the results of 
study IV may assure us that the use of small changes in inspiratory oxygen, probably do not affect 
the pulmonary circulation to a degree that has major impact on the results of the measurement.  
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Chapter 6: Conclusion and future perspective 
This thesis has elucidated the challenges in physiological assessments of COPD. It indicates that 
methods for both evaluation of pulmonary pathophysiology and evaluation of COPD severity are 
susceptible to the presence of comorbidities. Furthermore, it suggests a need of supplementary tools 
to measure lung function with simple techniques, which are possible to carry out at the bedside. 
Moreover, it has investigated two essential assumptions behind a tool, which possibly could be of 
use in COPD; the ALPE. One of these assumptions, the assumption that oxygen steady state could 
be achieved in 2-3 minutes, showed that modifications to the ALPE method were needed if the tool 
should be used in COPD; another assumption, that HPV does not affect the outcome of the 
measurement, is most likely to be a reasonable approximation. However, the thesis has also posed a 
number of questions that remain unanswered and therefore a number of interesting issues requiring 
further investigation.  
6.1 The GOLD combined assessment score – COPD severity or Risk Assessment? 
The results of study I indicate that the GOLD combined risk assessment score is sensitive to 
patients’ morbidity. As study I was a pilot study, further investigation should include a larger 
sample size to strengthen the statistical power. Future studies should also include measures of 
dynamic hyperinflation and a six-minute walking test, with these used to evaluate whether the 
pulmonary component of the disease is more pronounced in activity compared to rest.  
 
6.2 Pulmonary perfusion and COPD 
Study I and II of this thesis found that DLCO was associated with the GOLD stratification score. 
This indicates that DLCO could be used to monitor disease in COPD. However, the interesting 
question is – what does DLCO really measure in COPD? Both study I and study II suggest that 
pulmonary perfusion may relate to clinical findings in COPD; study II even speculates that DLCO 
may be a measure of pulmonary perfusion. The measurement of pulmonary perfusion has, in recent 
years, become more readily available, not least due to the availability of Magnetic Resonance 
Imaging (MRI). It may therefore be a useful measurement in investigating whether pulmonary 
perfusion has an impact on patients reported outcomes such as dyspnea, as suggested by 
unpublished data from study I. Pulmonary perfusion may also be interesting when investigating the 
interaction between different pathological findings, as illustrated in Figure 10. However, a number 
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of questions about the influence of pulmonary perfusion in COPD remain to be answered. These 
include: Questions about perfusion changes in relation to phenotypic presentations of COPD; 
longitudinal changes in perfusion; the influence of perfusion changes on morbidity and mortality in 
COPD and the influence on perfusion changes on the outcome of lung function measurements. 
Furthermore, an interesting question is whether pulmonary perfusion changes are reflected 
systemically, i.e. in peripheral muscles, heart and brain.  
    To pursue these questions, collaboration has been established between the author of this thesis 
and colleagues with interest in respiration and imaging at Aalborg University Hospital, along with 
an international collaboration with an Imaging Centre with experience in MRI-imaging of 
pulmonary perfusion.  
6.3 ALPE in relation to COPD-patients. 
Study III has shown that modifications were needed for ALPE to be used in COPD. ALPE essential 
can therefore, in its present form, not be applied directly in the diagnostic process or monitoring of 
COPD patients.  
    Study IV included a study population of patients with coronary heart disease. To secure that the 
findings are valid in COPD, a study on COPD patients should be carried out. 
    Even though the knowledge of V̇/Q̇ mismatch in COPD patients dates back to the 1970’s there 
has never been any approach to apply this knowledge into daily clinical practice. This may be 
understandable as the measure is difficult to obtain. If the use of this measurement is within reach, 
we need to relate V̇/Q̇ mismatch to define i.e. when V̇/Q̇ mismatch is mild, moderate and severe and 
to relate it to clinical features as dyspnea, desaturation etc., well known in COPD patients.  
    Study I of this study suggest that lung function parameters may be influenced by the presence of 
comorbidities. The question is whether this also applies to the ALPE method. As such, the question 
is to which extent the ALPE method is beneficial for further understanding and increasing 
diagnostic specificity in COPD? Large scale studies would be needed to elucidate this and the cost-
benefit of introducing a new method in the diagnostic procedure. 
    With modifications the ALPE method, it might be a step forward towards an easily applicable 
method, which not only provides information on pathological changes, but also allows the 
unmasking of the underlying pulmonary pathology. 
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